- Brainstorm Cell Therapeutics Inc Annual Shareholders Meeting TranscriptDec 18, 2023
- Q3 2023 Brainstorm Cell Therapeutics Inc Earnings Call TranscriptNov 14, 2023€0.16 (+23.08%)Earnings
- Brainstorm Cell Therapeutics Inc Investor Call TranscriptOct 18, 2023
- Q2 2023 Brainstorm Cell Therapeutics Inc Earnings Call TranscriptAug 14, 2023€1.45 (+1.40%)Earnings
- Q1 2023 Brainstorm Cell Therapeutics Inc Earnings Call TranscriptMay 15, 2023€2.52 (-3.08%)Earnings
- Q4 2022 Brainstorm Cell Therapeutics Inc Earnings Call TranscriptMar 30, 2023€2.2 (+39.05%)Earnings
- Brainstorm Cell Therapeutics Inc To Discuss The Company's Biologics License Application (BLA) for NurOwn(®) TranscriptMar 27, 2023
- Brainstorm Cell Therapeutics Inc Annual Shareholders Meeting TranscriptJan 10, 2023
- Brainstorm Cell Therapeutics Inc at EBD Group Biotech Showcase TranscriptJan 09, 2023
- Q3 2022 Brainstorm Cell Therapeutics Inc Earnings Call TranscriptNov 14, 2022€1.4 (-7.92%)Earnings
- Brainstorm Cell Therapeutics Inc ALS One Research Symposium TranscriptOct 07, 2022
- Q2 2022 Brainstorm Cell Therapeutics Inc Earnings Call TranscriptAug 15, 2022€3.57 (+26.70%)Earnings
- Q1 2022 Brainstorm Cell Therapeutics Inc Earnings Call TranscriptMay 16, 2022€2.69 (+2.99%)Earnings
- Q4 2021 Brainstorm Cell Therapeutics Inc Earnings Call TranscriptMar 28, 2022€3.04Earnings
- Q3 2021 Brainstorm Cell Therapeutics Inc Earnings Call TranscriptNov 15, 2021€2.6Earnings
- Brainstorm Cell Therapeutics Inc at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa (Virtual) TranscriptOct 12, 2021
- Q2 2021 Brainstorm Cell Therapeutics Inc Earnings Call TranscriptAug 05, 2021€3.14 (+0.64%)Earnings
- Q1 2021 Brainstorm Cell Therapeutics Inc Earnings Call TranscriptApr 26, 2021€2.82 (+4.44%)Earnings
- Q4 2020 Brainstorm Cell Therapeutics Inc Earnings Call TranscriptFeb 04, 2021€5.15Earnings
- Brainstorm Cell Therapeutics Inc to Present at the Alliance for Regenerative Medicine TranscriptJan 08, 2021
- Q3 2020 Brainstorm Cell Therapeutics Inc Earnings and Corporate Update Call TranscriptOct 15, 2020
- Brainstorm Cell Therapeutics Inc at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa (Virtual) TranscriptOct 12, 2020
- Q2 2020 Brainstorm Cell Therapeutics Inc Earnings and Corporate Update Call TranscriptAug 05, 2020
- Q1 2020 Brainstorm Cell Therapeutics Inc Earnings Call TranscriptMay 07, 2020€6.15 (-7.52%)Earnings
- Q4 2019 Brainstorm Cell Therapeutics Inc Earnings Call TranscriptFeb 18, 2020€5.1 (+8.51%)Earnings
- Brainstorm Cell Therapeutics Inc at Noble Financial Emerging Growth Investor Conference TranscriptFeb 17, 2020
- Brainstorm Cell Therapeutics Inc at 3rd Annual NIF Forum TranscriptJan 17, 2020
- Brainstorm Cell Therapeutics Inc looks forward to top-line results for its ALS Phase 3 program TranscriptJan 15, 2020
- Brainstorm Cell Therapeutics Inc at Sachs Associates Neuroscience Innovation Forum TranscriptJan 12, 2020
Brainstorm Cell Therapeutics Inc to Present at the Alliance for Regenerative Medicine Transcript
Hi, I'm Stacy Lindborg, I'm Executive Vice President and Head of Global Clinical Research at Brainstorm Cell Therapeutics. And I'm pleased to be here today speaking to you on behalf of the Company.
I'd like to start by introducing you to Brainstorm's unique cell therapy product. It's an autologous product, which means that we use a patient's own cells to produce their product. As part of the manufacturing, cryopreservation allows us to create an off-the-shelf product for each patient as one harvest of bone marrow creates several years of therapy.
From the point of harvesting bone marrow, the first treatment is available in 19 days with subsequent treatments being available in seven days. Attributes that contribute to the product being consistent and reliable include things like there are no animal proteins or antibiotics, genetic modifications, or viral vectors used.
NurOwn is culture rescued, creating a product with a very high sole viability and consistent performance characteristics.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)